Skip to main content
. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563

Figure 1.

Figure 1.

(A) Kaplan–Meier curves for progression free survival and overall survival for the OrienX010 dose escalation trial. The median PFS was 16.3 mo (497 d). Median OS has not been met. (B) Kaplan–Meier curves for progression free survival and overall survival for the DC–CIK therapy expansion trial. The median PFS was 9.9 mo (301 d). Median OS has not been met.